Everest Medicines Limited

SEHK:1952 Stock Report

Market Cap: HK$7.4b

Everest Medicines Management

Management criteria checks 1/4

Everest Medicines' CEO is Rogers Luo, appointed in Sep 2022, has a tenure of 1.58 years. total yearly compensation is CN¥30.72M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth HK$22.70M. The average tenure of the management team and the board of directors is 2.1 years and 2.6 years respectively.

Key information

Rogers Luo

Chief executive officer

CN¥30.7m

Total compensation

CEO salary percentage23.5%
CEO tenure1.6yrs
CEO ownership0.3%
Management average tenure2.1yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 31
Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Jan 31
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Sep 26
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

CEO Compensation Analysis

How has Rogers Luo's remuneration changed compared to Everest Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CN¥31mCN¥7m

-CN¥844m

Sep 30 2023n/an/a

-CN¥424m

Jun 30 2023n/an/a

-CN¥3m

Mar 31 2023n/an/a

-CN¥125m

Dec 31 2022CN¥8mCN¥2m

-CN¥247m

Compensation vs Market: Rogers's total compensation ($USD4.24M) is above average for companies of similar size in the Hong Kong market ($USD522.50K).

Compensation vs Earnings: Rogers's compensation has increased whilst the company is unprofitable.


CEO

Rogers Luo (53 yo)

1.6yrs

Tenure

CN¥30,722,000

Compensation

Mr. Yongqing Luo, also known as Rogers, is CEO & Executive Director of Everest Medicines Limited from September 19, 2022. He was President and General Manager of Greater China at Brii Biosciences Limited a...


Leadership Team

NamePositionTenureCompensationOwnership
Wei Fu
Executive Chairman6.8yrsno data0.60%
CN¥ 44.2m
Yongqing Luo
CEO & Executive Director1.6yrsCN¥30.72m0.31%
CN¥ 22.7m
Ian Ying Woo
CFO, President & Executive Director5.8yrsCN¥18.46m0.063%
CN¥ 4.7m
Jason M. Brown
Chief Business Officer4.7yrsno datano data
Wei Yang
Chief Scientific Officer3yrsno datano data
Rico Liang
Chief Product Officerless than a yearno datano data
Sandra Zeng
Chief Medical Officerless than a yearno datano data
Yee Wa Lau
Joint Company Secretaryno datano datano data
Leah Liu
Joint Company Secretary & VP of Corporate Affairs2.1yrsno datano data

2.1yrs

Average Tenure

50yo

Average Age

Experienced Management: 1952's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Wei Fu
Executive Chairman6.8yrsno data0.60%
CN¥ 44.2m
Yongqing Luo
CEO & Executive Director1.6yrsCN¥30.72m0.31%
CN¥ 22.7m
Ian Ying Woo
CFO, President & Executive Director5.3yrsCN¥18.46m0.063%
CN¥ 4.7m
Yifan Li
Independent Non-Executive Director3.6yrsCN¥401.00kno data
Ki Chul Cho
Non-Executive Directorless than a yearno datano data
Shidong Jiang
Independent Non-Executive Director3.6yrsCN¥401.00kno data
Hoi Yam Chui
Independent Non-Executive Director1.3yrsCN¥352.00kno data
Honggang Feng
Non-Executive Directorless than a yearno datano data

2.6yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 1952's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.